Gut flora may lead to better diagnosis tool for liver disease

May 23, 2016

Primary sclerosing cholangitis, also known as PSC, is a liver disease with no effective medical treatment. Liver transplantation is the only proven long-term treatment of PSC, although only a fraction of individuals with PSC will ultimately require it. The vast majority of patients with PSC also have inflammatory bowel disease (Crohn's disease or ulcerative colitis), possibly implying that the intestine plays a role in the origin of this PSC. Researchers from VIB, UZ Leuven and KU Leuven now describe for the first time how changes in the intestinal microbiota are specifically associated with this disease.

These novel insights are the result of a long-standing collaboration between the research groups of prof. Jeroen Raes (VIB/KU Leuven) and prof. Severine Vermeire (KU Leuven/UZ Leuven). Combining their expertise in metagenomics of the gut flora (Jeroen Raes lab) and clinical expertise in gastroenterology (Severine Vermeire lab), they make a successful alliance for unravelling the role of gut flora in the development of gastro-intestinal diseases. The first results of this collaboration are now published in the leading scientific journal Gut.

Prof. Jeroen Raes (VIB/KU Leuven): "Using massive DNA sequencing, we compared the gut bacteria in patients with PSC and in healthy people. Based on the differences found, we could develop a signature to diagnose PSC based on gut bacteria. Although very promising, our findings now need to be confirmed before they can be used in clinical practice."

The findings may not only lead to a novel diagnosis tool of PSC, they may also be the starting point for developing microbiota-based therapies. But there is still a long way to go.

Prof. Severine Vermeire (KU Leuven/UZ Leuven): "In the future, may be used to help identify PSC patients with a more or less aggressive , or patients that may benefit from microbiota-based therapies, such as fecal microbiota transplantation or targeted pre- and probiotics."

Both teams are planning to further investigate the complex interactions between the immune system and the intestinal microbiota in PSC .

Explore further: Drinking coffee may slow progression of liver disease

Related Stories

Drinking coffee may slow progression of liver disease

February 26, 2016
(HealthDay)—Regular coffee consumption seems to delay disease progression in alcoholic liver disease (ALD) and primary sclerosing cholangitis (PSC) patients with end-stage liver disease (ESLD) and increase long-term survival ...

Children with and without multiple sclerosis have differences in gut bacteria

May 16, 2016
In a recent study, children with multiple sclerosis had differences in the abundance of specific gut bacteria than children without the disease. Certain types of bacteria were either more or less abundant in children with ...

Psoriasis does not worsen total hip arthroplasty outcomes

February 18, 2016
(HealthDay)—For patients undergoing total hip arthroplasty (THA), neither psoriatic arthritis (PsA) nor cutaneous psoriasis (PsC) are risk factors for poor outcomes, according to a study published in the February issue ...

Consuming coffee linked to lower risk of detrimental liver disease, study finds

May 19, 2013
Regular consumption of coffee is associated with a reduced risk of primary sclerosing cholangitis (PSC), an autoimmune liver disease, Mayo Clinic research shows. The findings were being presented at the Digestive Disease ...

Drinking coffee, smoking may protect against cholangitis

July 8, 2014
(HealthDay)—Coffee consumption and smoking might protect against the development of primary sclerosing cholangitis (PSC), according to a study published in the June issue of Clinical Gastroenterology and Hepatology.

A new lead in the quest to understand Alzheimer's

May 19, 2016
A consortium of European researchers is pursuing a new and unexpected lead in Alzheimer's research. They are examining the intestinal microbiome and its effect on neurodegeneration. EPFL is coordinating the consortium, which ...

Recommended for you

Drug found that induces apoptosis in myofibroblasts reducing fibrosis in scleroderma

December 15, 2017
(Medical Xpress)—An international team of researchers has found that the drug navitoclax can induce apoptosis (self-destruction) in myofibroblasts in mice, reducing the spread of fibrosis in scleroderma. In their paper ...

How defeating THOR could bring a hammer down on cancer

December 14, 2017
It turns out Thor, the Norse god of thunder and the Marvel superhero, has special powers when it comes to cancer too.

Researchers track muscle stem cell dynamics in response to injury and aging

December 14, 2017
A new study led by researchers at Sanford Burnham Prebys Medical Discovery Institute (SBP) describes the biology behind why muscle stem cells respond differently to aging or injury. The findings, published in Cell Stem Cell, ...

'Human chronobiome' study informs timing of drug delivery, precision medicine approaches

December 13, 2017
Symptoms and efficacy of medications—and indeed, many aspects of the human body itself—vary by time of day. Physicians tell patients to take their statins at bedtime because the related liver enzymes are more active during ...

Time of day affects severity of autoimmune disease

December 12, 2017
Insights into how the body clock and time of day influence immune responses are revealed today in a study published in leading international journal Nature Communications. Understanding the effect of the interplay between ...

Estrogen discovery could shed new light on fertility problems

December 12, 2017
Estrogen produced in the brain is necessary for ovulation in monkeys, according to researchers at the University of Wisconsin-Madison who have upended the traditional understanding of the hormonal cascade that leads to release ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.